References
- Global vaccine market revenues in 2005, 2009 and 2015 (in billion U.S. dollars) [Internet]. 2015. [cited 2016 Apr 5]. Available from: http://www.statista.com/statistics/265102/revenues-in-the-global-vaccine-market/
- Complete List of Vaccines Licensed for Immunization and Distribution in the US [Internet]. Silver Spring (MD): U.S. Food and Drug Administration; 2015. [cited 2016 Apr 5]. Available from: http://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm093833.htm
- Cole LA. The anthrax letters: a medical detective story. Washington (DC): Joseph Henry Press/National Academies Press; 2003.
- Fauci AS. Biodefence on the research agenda. Nature. 2003;421(6925):787.
- Product development under the animal rule guidance for industry [Internet]. 2003. [cited 2016 Apr 5]. Available from: http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm399217.pdf
- FDA approval of avian flu vaccine moves preparedness forward [Internet]. 2013; FDA Press. [cited 2016 Apr 5]. Available from: http://www.hhs.gov/about/news/2013/11/22/fda-approval-of-avian-flu-vaccine-moves-preparedness-forward.html
- Goodman JL. Influenza: perspective on current season and update on preparedness [Internet]. Silver Spring (MD): U.S. Food and Drug Administration; 2013. Available from: http://www.fda.gov/NewsEvents/Testimony/ucm338939.htm
- BioThrax® (Anthrax Vaccine Adsorbed) Emergent BioSolutions [Internet]. 2015. [cited 2016 Apr 5]. Available from: http://www.fda.gov/downloads/BiologicsBloodVaccines/BloodBloodProducts/ApprovedProducts/LicensedProductsBLAs/UCM074923.pdf
- Metzger W, Mordmueller BG. Vaccines for preventing smallpox. Cochrane Database Syst Rev. 2007;3:CD004913.
- Nalca A, Zumbrun EE. ACAM2000: the new smallpox vaccine for United States Strategic National Stockpile. Drug Des Devel Ther. 2010;4:71–79.
- Kennedy JS, Greenberg RN. IMVAMUNE: modified vaccinia Ankara strain as an attenuated smallpox vaccine. Expert Rev Vaccines. 2009;8(1):13–24.
- Mundy A. Fight breaks out between vaccine firms. Wall St J [Internet]. 2010. [cited 2016 Apr 5]. Available from: http://online.wsj.com/article/SB10001424052748703627704575298504043411376.html
- Medical Countermeasures for Anthrax [Internet]. 2016. [cited 2016 Apr 5]. Available from: https://www.medicalcountermeasures.gov/barda/cbrn/anthrax.aspx
- Aebersold P. FDA experience with medical countermeasures under the animal rule. Adv Prev Med. 2012;2012:507571.
- Bolken TC, Hruby DE. Discovery and development of antiviral drugs for biodefense: experience of a small biotechnology company. Antiviral Res. 2008;77(1):1–5.
- Bowick GC, Barrett ADT. Comparative pathogenesis and systems biology for biodefense virus vaccine development. J Biomed Biotechnol. 2010;2010:236528.
- Essential medicines and health products [Internet]. 2015. [cited 2016 Apr 5]. Available from: http://www.who.int/medicines/emp_ebola_q_as/en/
- Osterholm M, Moore K, Ostrowsky J, et al. The Ebola Vaccine Team B: a model for promoting the rapid development of medical countermeasures for emerging infectious disease threats. Lancet Infect Dis. 2016;16(1):e1–e9.
- Smith BT, Inglesby TV, O’Toole T. Biodefense R&D: anticipating future threats, establishing a strategic environment. Biosecur Bioterror. 2003;1(3):193–202.
- Pronker ES, Weenen TC, Commandeur H, et al. Risk in vaccine research and development quantified. PLoS One. 2013;8(3):e57755.
- Biodefense market analysis by product (anthrax, smallpox, botulism, radiation/nuclear, ebola, hemorrhagic fever) and segment forecasts to 2020 [Internet]. 2015. [cited 2016 Apr 5]. Available from: http://www.grandviewresearch.com/industry-analysis/biodefense-market